ERBB2 and interstitial lung disease: As ILD has been observed in patients receiving ADCs with a range of different therapeutic targets, including human epidermal growth factor receptor 2 (HER2), folate receptor α, and trophoblast cell surface antigen 2, it is likely that the lung toxicity associated with ADCs is not related to any specific target protein [24].